Connect with us

Technology

WELL Health Announces Delay in Filing of Annual Audited Financial Statements Due to Matter Related to US Subsidiary Circle Medical

Published

on

VANCOUVER, BC, March 28, 2025 /PRNewswire/ – WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (“WELL” or the “Company”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announces that it will be delaying the filing of its audited annual consolidated financial statements for the year ended December 31, 2024, the related management’s discussion and analysis, and related CEO and CFO certificates (collectively, the “Required Filings”) beyond the March 31, 2025 deadline (the “Deadline”).

The delay is resulting from the accounting implications related to the Company’s non-wholly owned Delaware subsidiary Circle Medical Technologies, Inc. (“Circle Medical”), as described in further detail below. In fiscal 2023, Circle Medical contributed a net loss of $1.1 million to WELL’s consolidated net income of $16.6 million and contributed less than 2.7% to WELL’s consolidated Adjusted EBITDA(1).

In September 2024, Circle Medical received a request for the voluntary production of documents and information (“RFI”) from the Civil Division of the United States Attorney’s Office for the Northern District of California (“USAO”) investigating certain of Circle Medical’s billing practices in the US. Circle Medical has been responding to the RFI and engaging with the USAO to address and resolve this matter.  Additional information and analysis regarding the impact of the USAO RFI is necessary in order to finalise Circle Medical’s financial statements and by extension, the Company’s annual consolidated financial statements for the year ended December 31, 2024. The production of information by Circle Medical and analysis by the Company for the financial statements is not expected to be completed prior to the March 31, 2025 filing deadline for the Required Filings.

The Company does not expect the resolution of the matter to have a material effect on the Company’s cash position or available resources. The Company and Circle Medical are currently working diligently to finalise the Company’s annual consolidated financial statements at the earliest possible date. The Company currently expects to be in a position to file the Required Filings on or before April 15, 2025 (the “Filing Interval”).

Notwithstanding the foregoing, the Company confirms that it continues to seek strategic alternatives for Circle Medical and is committed to carrying out this process in due course.

The Company has applied to the British Columbia Securities Commission, as principal regulator for the Company, for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”) throughout the duration of the Filing Interval. However, there can be no assurance that a management cease trade order will be granted. The management cease trade order, if approved, will not affect the ability of persons who are not or have not been management of the Company to trade in its securities.

WELL confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports, if necessary, in the form of news releases for so long as it remains in default of the above-noted filing requirements. The British Columbia Securities Commission may issue a general cease trade order against WELL for failure to file the Required Filings within the prescribed time period or sooner if WELL fails to file the prescribed status reports.

Other than as disclosed herein, WELL is up to date in its filing obligations.

Footnote:

1.

Non-GAAP Financial Measures – Adjusted EBITDA

In addition to results reported in accordance with IFRS, the Company uses Adjusted EBITDA as a supplemental indicator of its financial and operating performance. The Company believes this non-GAAP financial measure reflects the Company’s ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization less (i) net rent expense on premise leases considered to be finance leases under IFRS and before (ii) transaction, restructuring, and integration costs, time-based earn-out expense, change in fair value of investments, share of income (loss) of associates, foreign exchange gain/loss, and stock-based compensation expense, and (iii) gains/losses that are not reflective of ongoing operating performance. The Company considers Adjusted EBITDA to be a financial metric that measures cash flow that can be used to fund working capital requirements, service future interest and principal debt repayments, and fund future growth initiatives. Adjusted EBITDA should not be considered an alternative to net income (loss), cash flow from operating activities, or other measures of financial performance defined under IFRS. A reconciliation of Adjusted EBITDA to the most directly comparable IFRS measure can be found in the Company’s Fiscal 2023 Annual MD&A.

WELL HEALTH TECHNOLOGIES CORP.

Per: “Hamed Shahbazi”

Hamed Shahbazi

Chief Executive Officer, Chairman and Director 

About WELL Health Technologies Corp.

WELL’s mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL’s comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL’s solutions enable more than 41,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 200 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL’s solutions are focused on specialized markets such as the gastrointestinal market, women’s health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol “WELL” and on the OTC Exchange under the symbol “WHTCF”. To learn more about the Company, please visit: www.well.company.

Forward-Looking Information

This news release contains “Forward-Looking Information” within the meaning of applicable Canadian securities laws, including, without limitation: statements regarding the grant of a management cease trade order, expected timing of the Required Filings, the impact of the resolution of the USAO RFI on WELL, and the ability to consummate strategic alternatives for Circle Medical. Forward-Looking Information is based on a number of estimates and assumptions are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond WELL’s control, which could cause actual results and events to differ materially from those disclosed in this news release. Forward-Looking Information generally can be identified by the use of forward-looking words such as “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “goal” or “continue”, or the negative thereof or similar variations. Forward-Looking Information involves known and unknown risks, uncertainties and other factors that may cause future results, performance, or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by the Forward-Looking Information and the Forward-Looking Information is not a guarantee of future results or performance. WELL’s comments expressed or implied by such Forward-Looking Information are subject to a number of risks, uncertainties, and conditions, many of which are outside of WELL’s control, and undue reliance should not be placed on such information. Forward-Looking Information are qualified in their entirety by inherent risks and uncertainties, including the risk factors identified in documents filed by WELL under its profile at www.sedar.com, including its most recent Annual Information Form and its most recent Management’s Discussion and Analysis. Except as required by securities law, WELL does not assume any obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/well-health-announces-delay-in-filing-of-annual-audited-financial-statements-due-to-matter-related-to-us-subsidiary-circle-medical-302414821.html

SOURCE WELL Health Technologies Corp.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Harness Delivers Unified AI Intelligence Across Software Delivery with Google Cloud

Published

on

By

Harness integrates Google Cloud’s Developer Connect into its Software Delivery Knowledge Graph to give engineering teams smarter, faster AI-driven insights

SAN FRANCISCO, April 22, 2026 /PRNewswire/ — Harness, the AI Software Delivery Platform™ company, today announced that it will bring together Harness’s Software Delivery Knowledge Graph and Google Cloud’s Developer Connect. The initiative gives joint customers a unified, AI-ready view of their entire software delivery lifecycle, and the intelligence to act on it with confidence.

The announcement was made at Google Cloud Next, where Harness also won the 2026 Google Cloud Technology Partner of the Year Award in the Application Development – DevOps category.

The Missing Piece in AI Software Delivery

Modern software delivery environments are inherently complex. Pipelines, services, build and deploy infrastructure, artifacts, and dependencies are deeply interconnected — and the data that describes how they relate to one another is scattered across dozens of tools. As organizations accelerate their adoption of AI-powered engineering, that fragmentation becomes a critical liability. AI is only as effective as the context it can access, and today, most AI agents are operating with an incomplete picture.

Harness is addressing this challenge head-on. By integrating Google Cloud Developer Connect insights into the Harness Software Delivery Knowledge Graph, joint customers gain a continuously updated, relationship-aware model of their software delivery environment that spans both platforms, bridging the visibility gap between development and production so that AI agents can operate with complete and reliable context. For engineering teams, this translates directly to making decisions grounded in situational awareness rather than generic training data, allowing them to execute complex workflows with greater accuracy.

Where the Partnership Comes to Life

For joint customers of Harness and Google Cloud, this integration means Harness AI can now make smarter, faster decisions on their behalf. By bringing together deployment event logs, runtime data, and application dependency information from Google Cloud into the Harness Software Delivery Knowledge Graph, teams gain a continuously updated, comprehensive view of their software delivery environment. When an issue arises, engineers can diagnose and remediate faster, trace problems back to specific source files or infrastructure, and link artifacts to the teams responsible for them, without having to manually piece together context from multiple systems.

The result is AI that works harder for customers. With richer context available upfront, AI agents can operate more efficiently, delivering answers and recommendations that reflect the true state of the environment. Everything teams need is in one place, and their AI has everything it needs to act on it confidently.

Security is central to how this integration was built. Data shared between Harness and Google Cloud is governed by enterprise-grade access controls, ensuring the right information reaches the right people within the guardrails organizations require.

“AI is only as powerful as the context behind it. Without it, teams fall into the AI Velocity Paradox: moving code faster than ever, but risking shipping software that is unverified, insecure, and unreliable,” said Jyoti Bansal, co-founder and CEO of Harness. “This is exactly what our expanded work with Google Cloud directly addresses, giving joint customers a unified view of their software delivery environment and AI that can actually reason across it. When context is complete, speed and confidence go hand in hand.”

A Collaboration That Keeps Deepening

This integration is the latest evolution of a long-standing collaboration between Harness and Google Cloud. Harness AI runs on Gemini Enterprise Agent Platform, and joint customers already benefit from expanded access through Google Cloud Marketplace. With this announcement, that work expands from the infrastructure layer into the application layer — and directly into how AI understands and acts on the software delivery environment. And it doesn’t stop there. The Harness MCP Server is now accessible within Google’s Gemini Enterprise app environment, enabling Gemini Enterprise customers to leverage Harness capabilities directly from their existing AI interface.

“Google Cloud provides cutting-edge technology that helps partners innovate and deliver more impactful solutions for business transformation,” said Ritika Suri, Managing Director, AI and Data Partnerships at Google Cloud. “Through our partnership with Harness, we will provide customers with innovative capabilities that can improve operations, enhance customer experiences, and drive innovation.”

Join Us

As our Knowledge Graph ecosystem continues to grow, Harness remains committed to expanding the breadth of integrations available to customers with the goal of being the most comprehensive AI-ready software delivery platform on the market.

To connect with the Harness team in person, visit the Harness booth at Google Cloud Next.

About Harness
Harness is the AI Software Delivery Platform™ company, enabling engineering teams to build, test, and deliver software faster and more securely. Powered by Harness AI and the Software Delivery Knowledge Graph, the platform brings intelligent automation to every stage of the software delivery lifecycle after code — removing toil and freeing developers from manual, repetitive work. Companies like United Airlines, Morningstar, and Choice Hotels use Harness to deploy up to 70% faster, reduce change failure rates by 50%, cut deployment effort by 80%, and lower security noise by 65%. Based in San Francisco, Harness is backed by Menlo Ventures, IVP, Unusual Ventures, and Citi Ventures.

View original content to download multimedia:https://www.prnewswire.com/news-releases/harness-delivers-unified-ai-intelligence-across-software-delivery-with-google-cloud-302749850.html

SOURCE Harness

Continue Reading

Technology

H.I.G. Capital Announces the Sale of Celerion

Published

on

By

MIAMI, April 22, 2026 /PRNewswire/ — H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $74 billion of capital under management, is pleased to announce that one of its affiliates has signed a definitive agreement to sell its portfolio company, Celerion Holdings, Inc. (“Celerion” or the “Company”), a global CRO and leader in clinical pharmacology and bioanalytical sciences, to funds affiliated with THL Partners (“THL”).

Headquartered in Lincoln, Nebraska, Celerion is a leading provider of highly specialized clinical pharmacology and bioanalytical sciences with deep expertise in first-in-human dose escalation, cardiac safety (TQT), drug-drug interaction, and other complex clinical pharmacology studies that support regulatory approval and drug labeling. Celerion offers an integrated suite of services spanning data management, biostatistics, and clinical monitoring that supports a global base of pharmaceutical and biotechnology customers through its purpose-built clinical and laboratory infrastructure with facilities in Lincoln, Phoenix, Zurich, and Belfast.

H.I.G. acquired Celerion in November 2022 and worked closely with management to accelerate growth and strengthen the Company’s market position. During its ownership, H.I.G. supported strategic investments across commercial, operational, and technology initiatives, including the expansion of Celerion’s clinical and bioanalytical laboratory footprint. These efforts drove exceptional growth and solidified Celerion’s standing as a leading, clinical pharmacology-focused, contract research organization.

Susan Thornton, Celerion’s President & CEO, commented, “H.I.G. has been an exceptional partner to Celerion, helping us accelerate key strategic initiatives and invest meaningfully in our people, capabilities, and infrastructure. These efforts have strengthened our platform and enhanced the quality and consistency of outcomes we deliver to customers. We are excited to carry this momentum forward with THL as we enter our next phase of growth.”

Mike Gallagher, Managing Director at H.I.G., commented, “We are proud of what Celerion’s best-in-class team has accomplished during our partnership. The team has delivered industry- leading growth during our ownership, and we are confident it is uniquely positioned for its next chapter.”

Michael Kuritzky, Managing Director at H.I.G., added, “We are very proud of the work Celerion does to help drug sponsors worldwide navigate the complexities of clinical trial management. It has been a privilege to partner with Susan and her team, and we look forward to Celerion’s continued success.”

BofA Securities, Inc. and Lazard Frères & Co. LLC were financial advisors to H.I.G. and Celerion. McDermott Will & Schulte LLP was legal counsel for H.I.G. and Celerion in connection with the transaction.

About Celerion

Celerion is a clinical research organization that provides comprehensive clinical trial solutions to pharmaceutical and biotechnology clients conducting early clinical research throughout North America, Europe, and Asia. The Company serves its clients through a global network of facilities and provides first-in-human to proof-of-concept studies as well as bioanalytical laboratory services, data management and biometrics, and drug development services. For more information, visit celerion.com.

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $74 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Los Angeles, New York, San Francisco, and Stamford in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, Dubai, and Hong Kong, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach:

H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

*Based on total capital raised by H.I.G. Capital and its affiliates.

Contact:

Mike Gallagher
Managing Director
mgallagher@hig.com

Michael Kuritzky
Managing Director
mkuritzky@hig.com

Alex Zisson
Managing Director
azisson@hig.com

H.I.G. Capital
1450 Brickell Avenue
31st Floor
Miami, FL 33131
P: 305.379.2322
hig.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/hig-capital-announces-the-sale-of-celerion-302749396.html

SOURCE H.I.G. Capital

Continue Reading

Technology

Coco Robotics Launches with Uber Eats in San Jose, Expanding Autonomous Delivery Across the U.S.

Published

on

By

The launch brings on-demand robot delivery to San Jose, California — one of the country’s leading hubs for technology, food, and innovationCoco will launch with Uber Eats, bringing AV delivery to customers and merchants across the city

SAN JOSE, Calif., April 22, 2026 /PRNewswire/ — Coco Robotics, the world’s largest urban robot delivery platform and recently named one of Fast Company’s World’s Most Innovative Companies in logistics, today announced the expansion of its autonomous delivery service to San Jose in California. The company’s robots are now active, giving residents, workers, and businesses in the city’s urban core access to fast, zero-emission last-mile delivery on Uber Eats. The launch marks Coco’s latest U.S. market expansion as the company scales its fleet toward thousands of robots globally.

“San Jose has always embraced technology, and welcoming Coco Robotics to our downtown reflects that spirit,” said San Jose Mayor Matt Mahan. “What I’m most encouraged by is that autonomous deliveries in our city will help restaurants and merchants fulfill more orders efficiently and safely, helping drive stronger business performance and greater customer reach. This innovation supports more sustainable and resilient businesses at the heart of our community. We look forward to the rollout of initial operations and to building a long-term program that enables Coco to grow and scale in San Jose.”

Downtown San Jose serves as Coco’s launch zone for its Bay Area debut – a dense, walkable urban hub with hundreds of restaurants and merchants. As the commercial center of Silicon Valley, it draws tens of thousands of tech, finance, and business workers who rely on fast, on-demand delivery throughout the day. The fleet is purpose-built for this environment, navigating sidewalks to complete quick, reliable, zero-emission deliveries.

“We’ve been serving a high volume of takeout orders in downtown San Jose, and demand keeps growing,” said Thuy Vu, owner of Thai Chili Express in Downtown San Jose. “Parking is always a challenge in this area, especially during peak hours, so anything that helps us get orders out faster is a big win. We’re excited for our guests to have another convenient delivery option through Coco, and we can see how this could help us operate more efficiently during our busiest times. It’s also really cool to see this kind of technology showing up in our neighborhood and becoming part of how we serve guests every day.”

“San Jose is exactly the kind of city Coco was built for,” said Zach Rash, Co-Founder and CEO of Coco Robotics. “It has hundreds of restaurants, a world-class food scene, and a downtown full of tech and finance professionals who want great food delivered quickly and reliably. These are busy people who value their time, and Coco gives them a faster, cleaner way to get what they want without leaving their office. It also helps reduce traffic and take pressure off parking in dense urban areas. We’re excited to bring that experience to San Jose.”

“We’re thrilled to bring Coco’s autonomous delivery robots to San Jose, offering a new and innovative way for customers to enjoy their favorite local spots,” said Aaron Emrich, Head of Autonomous Delivery at Uber Eats. “This launch marks another step forward in expanding advanced delivery technology, and we look forward to growing it in partnership with the San Jose community and everyone who uses our platform.”

The San Jose expansion builds on Coco’s proven track record across major U.S. cities including Los Angeles, Chicago, Jersey City, and Miami. The company has completed more than 500,000 zero-emission deliveries to date and operates the industry’s largest dataset of sidewalk robot operations, built from millions of miles navigating complex urban environments. That operational intelligence allows Coco’s fleet to adapt quickly to new cities and begin delivering at scale from day one.

About Coco Robotics

Coco Robotics is the world’s largest urban robotics platform, combining autonomous robots, real-world operations data, and advanced AI to power smarter, more efficient city logistics. Founded in 2020, Coco has completed over 500,000 zero-emission deliveries across the U.S. and Europe. The fleet continuously learns from millions of miles of real-world operations, giving Coco instant adaptability to new cities and environments. This data-driven intelligence allows Coco to expand rapidly while maintaining safe, reliable, and efficient operations. Coco’s mission is to create more sustainable, reliable, and affordable last-mile logistics solutions in cities around the world. For more information, visit www.cocodelivery.com.

About Uber

Uber’s mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 72 billion trips later across mobility and delivery, we’re building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/coco-robotics-launches-with-uber-eats-in-san-jose-expanding-autonomous-delivery-across-the-us-302750349.html

SOURCE Coco Robotics

Continue Reading

Trending